君实生物：自愿披露关于偌考奇拜单抗注射液新药上市申请获得受理的公告

Core Viewpoint - Junshi Biosciences has received the acceptance notice from the National Medical Products Administration for its new drug application for JS005, a monoclonal antibody injection for treating moderate to severe plaque psoriasis in adults [1] Group 1 - The product JS005 is a recombinant humanized anti-IL-17A monoclonal antibody injection [1] - The indication for JS005 is for adult patients suitable for systemic therapy or phototherapy for moderate to severe plaque psoriasis [1]